Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas.
Continuous bromocriptine treatment was given throughout pregnancy to 10 pregnant women with prolactinomas. The dosage of bromocriptine was modified to reduce the serum prolactin level to below 20 ng/ml. Eight patients had continuous bromocriptine treatment started early in their pregnancies, and no tumor-related neurological complications were observed. Continuous bromocriptine treatment was not started at the onset of pregnancy in two patients, and bitemporal hemianopia occurred (at 5 and 7 months of pregnancy). With the start of continuous bromocriptine treatment, a normalization of the visual fields rapidly ensued. The course of the pregnancies and the condition of the newborn infants at birth were normal. The subsequent mental and physical development of the newborn infants (observed up to the age of 6 years) was also normal.
D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage*; D002657:Child Development; D002675:Child, Preschool; D005260:Female; D006423:Hemianopsia / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010911:Pituitary Neoplasms / Q000378:metabolism*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000517:prevention & control*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D012189:Retrospective Studies; D013973:Thyrotropin-Releasing Hormone; D014794:Visual Fields
D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin